UNION therapeutics A/S - CVR: 33963750

2023,

21.03.2024

Bruttoresultat

Na.

Primær drift

Na.

Årets resultat

Na.

Aktiver

Na.

Kortfristede aktiver

Na.

Egenkapital

Na.

Afkastningsgrad

0 %

Soliditetsgrad

0 %

Likviditetsgrad

0 %

Resultat

21.03.2024

Årsrapport	2023 21.03.2024	2022 24.04.2023	2021 02.05.2022	2020 31.05.2021	2019 04.08.2020	2018 31.05.2019	2017 31.05.2018
Nettoomsætning								0	315.394	728.695	690.674
Resultat af primær drift	0	0	0	-7.817.532	-6.122.831	-520.133	-288.813
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0
Finansielle indtægter	0	0	0	16.826	4.798	805	3.024
Finansieringsomkostninger	0	0	0	-867.749	-136.437	-1.785	-4.147
Andre finansielle omkostninger	0	0	0
Resultat før skat	0	0	0	-8.668.455	-6.254.470	-521.113	-289.936
Resultat	0	0	0	-7.798.346	-5.396.630	-485.441	-223.943
Forslag til udbytte	0	0	0

Aktiver

21.03.2024

Årsrapport	2020 31.05.2021	2019 04.08.2020	2018 31.05.2019	2017 31.05.2018
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	0	394	15.845	26.271
Likvider	3.301.455	2.228.549	532.054	157.945
Kortfristede aktiver	4.368.805	3.691.707	772.978	236.391
Immaterielle aktiver og goodwill	0	0	0	0
Finansielle anlægsaktiver
Materielle aktiver	9.160	7.661	0	1.881
Langfristede aktiver	25.826	24.850	2.530	9.110
Aktiver	4.394.631	3.716.557	775.508	245.501

Aktiver

21.03.2024

Passiver

21.03.2024

Årsrapport	2023 21.03.2024	2022 24.04.2023	2021 02.05.2022	2020 31.05.2021	2019 04.08.2020	2018 31.05.2019	2017 31.05.2018
Forslag til udbytte	0	0	0
Egenkapital	0	0	0	-5.293.947	1.944.103	-194.987	-70.637
Hensatte forpligtelser	0	0	0
Langfristet gæld til banker	0	0	0
Anden langfristet gæld		0	0
Langfristede forpligtelser				9.025.669	401.133	732.234	63
Kortfristede forpligtelser				662.909	1.371.321	238.261	316.075
Leverandører af varer og tjenesteydelser	0	0	0
Kortfristede forpligtelser	0	0	0
Gældsforpligtelser	0	0	0
Forpligtelser	0	0	0	9.688.578	1.772.454	970.495	316.138
Passiver	0	0	0	4.394.631	3.716.557	775.508	245.501

Passiver

21.03.2024

Nøgletal

21.03.2024

Årsrapport	2023 21.03.2024	2022 24.04.2023	2021 02.05.2022	2020 31.05.2021	2019 04.08.2020	2018 31.05.2019	2017 31.05.2018
Afkastningsgrad	Na.	Na.	Na.	-177,9 %	-164,7 %	-67,1 %	-117,6 %
Dækningsgrad
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	Na.	Na.	Na.	147,3 %	-277,6 %	249,0 %	317,0 %
Payout-ratio	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	-900,9 %	-4.487,7 %	-29.139,1 %	-6.964,4 %
Soliditestgrad	Na.	Na.	Na.	-120,5 %	52,3 %	-25,1 %	-28,8 %
Likviditetsgrad	Na.	Na.	Na.

Resultat

21.03.2024

Gæld

21.03.2024

Årsrapport

21.03.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 21.03.2024)

Beretning

21.03.2024

Dato for ledelsens godkendelse af årsrapporten:2024-02-06

Ledelsespåtegning:Statement by the Board of Directors and the Executive ManagementThe Board of Directors and the Executive Man-agement have today discussed and approved the annual report of UNION therapeutics A/S for the financial year January 1 – December 31, 2023. The annual report has been prepared in ac-cordance with IFRS accounting standards as adopted by the EU, and further requirements in the Danish Financial Statements Act. In our opinion, the consolidated financial state-ments and the parent company financial state-ments give a true and fair view of the financial position of the group and the parent company at December 31, 2023 and of the results of their operations and cash flows for the financial year January 1 – December 31, 2023. Further, in our opinion, the management’s review includes a fair review of developments in the group’s and the parent company’s activi-ties and finances, results for the year and the group’s and the parent company’s financial position in general, as well as a description of the most significant risks and uncertainties to which the group and the parent company are exposed. We recommend that the annual report be ap-proved at the annual general meeting.